Patient and treatment characteristics
| Factor | Category | Cohort A (n=72) n (%) | Cohort B (n=39) n (%) | Combined cohorts (n=111) n (%) |
| Clinical site | Tübingen | 53 (73.6) | 34 (87.2) | 87 (78.4) |
| Lübeck | 4 (5.6) | 4 (3.6) | ||
| Dresden | 15 (20.8) | 5 (12.8) | 20 (18.0) | |
| Treatment | Pembrolizumab or nivolumab | 35 (48.6) | 11 (28.2) | 46 (41.4) |
| 2 mg/kg Q3W pembrolizumab | 31 | 3 | 34 | |
| 3 mg/kg Q3W pembrolizumab | 4 | 4 | ||
| 3 mg/kg Q2W nivolumab | 1 | 1 | ||
| 480 mg Q4W nivolumab | 7 | 7 | ||
| Nivolumab and ipilimumab | 37 (51.4) | 28 (71.8) | 65 (58.6) | |
| 1 mg/kg IPI +3 mg/kg Nivo Q3W | 1 | 4 | 5 | |
| 3 mg/kg IPI +1 mg/kg Nivo Q3W | 36 | 24 | 60 | |
| Age (years) | ≤50 | 10 (13.9) | 8 (20.5) | 18 (16.2) |
| 51–60 | 16 (22.2) | 10 (25.6) | 26 (23.4) | |
| 61–70 | 10 (13.9) | 8 (20.5) | 18 (16.2) | |
| 71–80 | 29 (40.3) | 9 (23.1) | 38 (34.2) | |
| >80 | 7 (9.7) | 4 (10.3) | 11 (9.9) | |
| Median age | 68 | 64 | 67 | |
| Sex | Female | 28 (38.9) | 13 (33.3) | 41 (36.9) |
| Male | 44 (61.1) | 26 (66.7) | 70 (63.1) | |
| M category (AJCC) | M1a | 13 (18.1) | 1 (2.6) | 14 (12.6) |
| M1b | 19 (26.4) | 4 (10.3) | 23 (20.7) | |
| M1c | 40 (55.6) | 34 (87.2) | 74 (66.7) | |
| LDH | Elevated | 32 (44.4) | 15 (38.5) | 47 (42.3) |
| Normal | 40 (55.6) | 23 (59.0) | 63 (56.8) | |
| n.d. | 1 (2.6) | 1 (0.9) |
LDH, lactate dehydrogenase; n.d., no data.